Anton Hagenbeek - Concepedia

Author

Anton Hagenbeek

Rotterdam University of Applied Sciences

Also Known As

A HAGENBEEK, A Hagenbeek, A. HAGENBEEK, A. Hagenbeek, Anton Hagenbeek, Arno Hagenbeek, Florida Jacksonville, Hagenbeek A., Hagenbeek, A., Hagenbeek, Anton

396

Publications

26.8K

Citations

H-Index

131

Concepts

All Affiliations

Rotterdam University of Applied Sciences Amsterdam UMC Location University of Amsterdam University Medical Center Utrecht Netherlands Organisation for Applied Scientific Research Erasmus University Rotterdam

About

Anton Hagenbeek is an author at Rotterdam University of Applied Sciences specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	63	3.5K
2	Health Sciences	16	20	707
3	Engineering	2	2	28
4	Natural Sciences	1	1	48
5	Allergy	1	1	54

Anton Hagenbeek

164

Publications

21.1K

Citations

H-Index

Page 1

	Year	Citations
Revised Response Criteria for Malignant Lymphoma Bruce D. Cheson, Beate Pfistner, Malik E. Juweid, Journal of Clinical Oncology	2007	4.4K
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma Thierry Philip, Cesare Guglielmi, Anton Hagenbeek, New England Journal of Medicine	1995	2.4K
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial Gilles Salles, John F. Seymour, Fritz Offner, The Lancet Lymphoid NeoplasiaOncologyPhase 3Follicular LymphomaPathology	2010	1.1K
Follicular lymphoma international prognostic index. Pascal Roy, Philippe Colombat, Josephine M White, PubMed	2004	627
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial Marinus H. J. van Oers, Richard Klasa, Robert Marcus, Blood	2006	592
Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma Franck Morschhauser, John Radford, Achiel Van Hoof, Journal of Clinical Oncology	2008	458
Second cancer risk following Hodgkin's disease: a 20-year follow-up study. Flora E. van Leeuwen, Willem J. Klokman, Anton Hagenbeek, Journal of Clinical Oncology	1994	447
Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease Christophe Fermé, Houchingue Eghbali, J.H. Meerwaldt, New England Journal of Medicine	2007	444
Long-Term Risk of Second Malignancy in Survivors of Hodgkin’s Disease Treated During Adolescence or Young Adulthood Flora E. van Leeuwen, Willem J. Klokman, Mars B. vanʼt Veer, Journal of Clinical Oncology	2000	437
Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study Marinus H. J. van Oers, M. van Glabbeke, L. Giurgea, Journal of Clinical Oncology	2010	336

Page 1